Last updated: 2026-09-16 09:46:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Tonix Pharmaceuticals Holding Corp. (TNXP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.45, with a market capitalisation of $201.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.40 to $29.19. This page covers its latest market performance, valuation, price trends and company information.
$201.18M | |
$11.85 | |
$13,440,000,000.00 | |
$6.76 | |
$11.62 | |
282.00 | |
490.43K | |
-- | |
$29.19 | |
$9.40 | |
-- | |
-- |
Tonix Pharmaceuticals Holding Corp. (TNXP) is trading at $12.45 in pre-market trading as of 2026-09-16 09:24:00, up 7.14% ($0.83) from the previous close of $11.62
Pre-market trading shows how investors are pricing TNXP before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Tonix Pharmaceuticals Holding Corp. (TNXP) moved from $13.14 to $12.45, representing a decline of 5.25% ($0.69).
The stock traded between $11.52 and $13.48 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 332.57 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 15.4%
TNXP is currently trading at $12.45, placing it 15.4% of the way from its 52-week low of $9.40 to its 52-week high of $29.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 142 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tonix Pharmaceuticals Holding Corp. (TNXP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.